

Supplementary materials

The supplemental materials includes supplemental figures.




Figure S1. *CD97* Z-score and mRNA expression distribution. (A) Histogram of *CD97* Log2 transformed mRNA expression; (B) *CD97* mRNA expression Z score; (C) Scatterplot of *CD97* Z-score vs *CD97* log2 mRNA expression. Relative *CD97* log2 mRNA expression categorized by (D) FAB classification; (E) cytogenetic status and (F) risk status. (G) *CD97* expression in relapsed vs. de novo AML samples from the BEAT AML cohort analyzed using Vizome tool. * $P < 0.05$ ** $P < 0.01$




Figure S2. Survival analysis of AML patients according to *CD97* expression. (A) Overall Survival of 173 AML Patients with *CD97* Z-score > 2 and *CD97* Z-score < 2 ; (B) Disease-free Survival of 171 AML Patients with *CD97* Z-score > 2 and *CD97* Z-score < 2 .




Figure S3. Survival analysis of AML patients with APL according to *CD97* expression. (A) Overall Survival of AML patients with APL with *CD97* Z-score ≥ 1 and *CD97* Z-score < 1 ; (B) Disease-free Survival of AML patients with APL with *CD97* Z-score ≥ 1 and *CD97* Z-score < 1 .




Figure S4. *CD97* mRNA expression distribution. Histogram of *CD97* mRNA expression of (A) Metzeler-163 dataset; (B) Metzeler-79 dataset; (C) Bullinger dataset.




Figure S5. Survival analysis of AML patients according to *CD97* expression after stratification based on *NPM1* mutation status (A) Disease free Survival of AML patients with *CD97* high (Z-score ≥ 1) vs *CD97* low (Z-score < 1) in patients with *NPM1* wild type gene. (B) Disease free Survival of AML patients with *CD97* high (Z-score ≥ 1) vs *CD97* low (Z-score < 1) in patients with *NPM1* mutation. (C) OS AML patients with *CD97* high (Z-score ≥ 1) vs *CD97* low (Z-score < 1) in patients with FLT3 and *NPM1* mutation





Figure S6. Survival analysis of AML patients according to *CD97* expression after stratification based on age. (A) Disease free Survival of AML patients with *CD97* high (Z-score \geq 1) vs *CD97* low (Z-score $<$ 1) in patients \geq 60 years of age. (B) Disease free Survival of AML patients with *CD97* high (Z-score \geq 1) vs *CD97* low (Z-score $<$ 1) in patients $<$ 60 years of age

Z-SCORE>2 COMPARISON ANALYSIS



CD97 Z-SCORE<-1




Figure S7. Cell signaling pathway analysis associated with CD97 Patients were grouped in CD97 high ($Z > 2$) and CD97 low ($Z < -1$). Pearson correlation scores of CD97 vs all the available gene expression data in TCGA were calculated and analyzed in ingenuity pathway analysis